Endonovo Therapeutics(ENDV)
$0.00+0.00 (+100.00%)
ENDV
Endonovo Therapeutics financials statements
$0.00
At close:+0.00 (+100.00%)
Want to see ENDV full AI Analyst Report?
Endonovo Therapeutics (ENDV) Ratios
24 Followers
Endonovo Therapeutics Ratios
ENDV's free cash flow for Q2 2026 was $-49.82K. For the 2026 fiscal year, ENDV's free cash flow was increased by $4.00 and operating cash flow was $-49.82K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -0.08 | -0.08 | 0.31 | -0.53 | -0.14 |
| Operating Cash Flow Ratio | -0.00 | 0.00 | 0.00 | -0.02 | -0.06 |
| Short-Term Operating Cash Flow Coverage | -0.01 | 0.01 | 0.02 | -0.09 | -0.14 |
| Net Current Asset Value | $ -28.88M | $ -26.80M | $ -24.73M | $ -33.45M | $ -17.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 358.24 | 356.14 | 11.06 | 5.58 | 3.58 |
| Debt-to-Equity Ratio | -0.24 | -0.26 | -0.29 | -0.22 | -0.46 |
| Debt-to-Capital Ratio | -0.31 | -0.34 | -0.42 | -0.29 | -0.84 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.00 | -0.03 | -0.04 | -0.13 |
| Debt Service Coverage Ratio | -0.12 | -0.12 | 1.06 | -1.95 | -0.19 |
| Interest Coverage Ratio | -0.76 | -1.26 | -2.28 | -2.47 | -2.36 |
| Debt to Market Cap | 62.97 | 31.58 | 2.94 | 2.85 | 7.69 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.03 | 0.06 | 0.14 |
| Net Debt to EBITDA | -7.31 | -7.30 | 0.80 | -0.43 | -4.68 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -6125.64% | -366.87% | 92.62% | 79.50% |
| EBIT Margin | 0.00% | -15532.54% | 5851.95% | -12672.79% | -2959.21% |
| EBITDA Margin | 0.00% | -9373.70% | 6313.23% | -12194.86% | -2072.14% |
| Operating Profit Margin | 0.00% | -15532.54% | -2081.72% | -2411.69% | -3045.68% |
| Pretax Profit Margin | 0.00% | -27853.20% | 4937.60% | -13649.17% | -4247.17% |
| Net Profit Margin | 0.00% | -27853.20% | 4937.60% | -13649.17% | -4247.17% |
| Continuous Operations Profit Margin | 0.00% | -27853.20% | 4937.60% | -13649.17% | -4247.17% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 230.09% | 179.32% | -237.19% | 565.96% | 139.45% |
| Return on Assets (ROA) | -11275.28% | -14502.03% | 1082.55% | -1441.92% | -154.69% |
| Return on Equity (ROE) | 7.54% | 10.44% | -28.73% | 57.41% | 19.68% |
| Return on Capital Employed (ROCE) | 3.28% | 5.84% | 12.15% | 10.17% | 14.19% |
| Return on Invested Capital (ROIC) | 4.32% | 7.86% | 17.22% | 13.08% | 26.15% |
| Return on Tangible Assets | -11275.28% | -14502.03% | 32780.69% | -116766.75% | -3273.31% |
| Earnings Yield | -1982.05% | -1285.83% | 288.01% | -737.31% | -332.63% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 77.44 |
| Payables Turnover | 0.00 | 0.18 | 0.61 | 0.01 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.52 | 0.22 | 0.11 | 0.04 |
| Working Capital Turnover Ratio | 0.00 | -0.00 | -0.00 | -0.01 | -0.00 |
| Cash Conversion Cycle | 0.00 | -2000.71 | -601.84 | -32209.51 | -16030.88 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 4.71 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2000.71 | 601.84 | 32209.51 | 16035.59 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 4.71 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | 0.00 | 0.00 | -0.00 | -0.02 |
| Free Cash Flow Per Share | -0.00 | 0.00 | 0.00 | -0.00 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 33495.67 | 0.00 | 0.00 | -246646.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 33495.67 | 0.00 | 0.00 | -246646.00 |
| Operating Cash Flow Coverage Ratio | -0.01 | 0.01 | 0.02 | -0.09 | -0.14 |
| Operating Cash Flow to Sales Ratio | 0.00 | 10.01 | 0.87 | -5.02 | -13.50 |
| Free Cash Flow Yield | -39.16% | 46.19% | 5.07% | -27.09% | -105.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.05 | -0.08 | 0.35 | -0.14 | -0.30 |
| Price-to-Sales (P/S) Ratio | 0.00 | 21.66 | 17.14 | 18.51 | 12.77 |
| Price-to-Book (P/B) Ratio | -0.00 | -0.01 | -0.10 | -0.08 | -0.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.55 | 2.16 | 19.73 | -3.69 | -0.95 |
| Price-to-Operating Cash Flow Ratio | -2.55 | 2.16 | 19.73 | -3.69 | -0.95 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Enterprise Value Multiple | -7.43 | -7.53 | 1.07 | -0.59 | -5.30 |
| Enterprise Value | 7.02M | 7.09M | 9.48M | 9.66M | 8.03M |
| EV to EBITDA | -7.43 | -7.53 | 1.07 | -0.59 | -5.30 |
| EV to Sales | 0.00 | 705.68 | 67.56 | 71.36 | 109.82 |
| EV to Free Cash Flow | -163.38 | 70.53 | 77.75 | -14.23 | -8.14 |
| EV to Operating Cash Flow | -163.38 | 70.53 | 77.75 | -14.23 | -8.14 |
| Tangible Book Value Per Share | -0.03 | -0.05 | -0.09 | -0.24 | -0.30 |
| Shareholders’ Equity Per Share | -0.03 | -0.05 | -0.09 | -0.23 | -0.26 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.01 | 0.03 | -0.13 | -0.05 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.30 | 1.79 | 0.84 | 1.08 | 1.44 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 94.07 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 4.90 | 0.33 | 1.30 |
| Income Quality | 0.02 | -0.04 | 0.02 | 0.04 | 0.32 |
Currency in USD
